These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 1197588

  • 1. Behavioural sequelae of dopaminergic degeneration: postsynaptic supersensitivity?
    Creese I, Iversen SD.
    Psychopharmacol Bull; 1975 Oct; 11(4):12-3. PubMed ID: 1197588
    [No Abstract] [Full Text] [Related]

  • 2. Behavioral correlates of dopaminergic supersensitivity.
    Iversen SD, Creese I.
    Adv Neurol; 1975 Oct; 9():81-92. PubMed ID: 1170717
    [No Abstract] [Full Text] [Related]

  • 3. Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons.
    Ungerstedt U, Ljungberg T, Steg G.
    Adv Neurol; 1974 Oct; 5():421-6. PubMed ID: 4531217
    [No Abstract] [Full Text] [Related]

  • 4. Behavioral effects of direct- and indirect-acting dopaminergic agonists.
    Moore KE.
    Adv Biochem Psychopharmacol; 1974 Oct; 12(0):403-14. PubMed ID: 4371765
    [No Abstract] [Full Text] [Related]

  • 5. Dopaminergic--GABA-ergic interaction in the nigrostriatal system.
    Koltai MZ, György L.
    Acta Physiol Acad Sci Hung; 1981 Oct; 58(3):225-33. PubMed ID: 7348023
    [Abstract] [Full Text] [Related]

  • 6. The effects of dopaminergic denervation on Na+-K+ ATPase activity and 3H-ouabain binding in rat corpus striatum.
    Bjur RA, Westfall DP.
    Proc West Pharmacol Soc; 1984 Oct; 27():35-8. PubMed ID: 6093132
    [No Abstract] [Full Text] [Related]

  • 7. Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.
    Wolfarth S.
    Pol J Pharmacol Pharm; 1976 Oct; 28(5):469-93. PubMed ID: 796834
    [No Abstract] [Full Text] [Related]

  • 8. 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome.
    Ungerstedt U.
    Pharmacol Ther B; 1976 Oct; 2(1):37-40. PubMed ID: 772721
    [No Abstract] [Full Text] [Related]

  • 9. Proceedings: Behavioral effects of direct and indirect acting dopaminergic agonists.
    Moore KE.
    Psychopharmacol Bull; 1974 Jul; 10(3):41-2. PubMed ID: 4419323
    [No Abstract] [Full Text] [Related]

  • 10. Striatal cell supersensitivity to apomorphine in dopamine-lesioned rats correlated to behaviour.
    Schultz W, Ungerstedt U.
    Neuropharmacology; 1978 Jun; 17(6):349-53. PubMed ID: 566861
    [No Abstract] [Full Text] [Related]

  • 11. Antiparkinsonian drugs and dopaminergic neostriatal mechanisms: studies in rats with unilateral 6-hydroxydopamine (=6-OH-DA)-induced degeneration of the nigro-neostriatal DA pathway and quantitative recording of rotational behaviour.
    Fuxe K, Ungerstedt U.
    Pharmacol Ther B; 1976 Jun; 2(1):41-7. PubMed ID: 817332
    [No Abstract] [Full Text] [Related]

  • 12. Effects of chronic morphine treatment on dopamine-mediated turning behaviour in rats and mice with 6-hydroxydopamine-induced unilateral nigro-striatal lesions.
    Slater P, Crossman AR.
    Neuropharmacology; 1980 Mar; 19(3):289-95. PubMed ID: 7191487
    [No Abstract] [Full Text] [Related]

  • 13. Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa.
    Ogawa N, Edamatsu R, Mizukawa K, Asanuma M, Kohno M, Mori A.
    Adv Neurol; 1993 Mar; 60():242-50. PubMed ID: 8380518
    [No Abstract] [Full Text] [Related]

  • 14. Dopamine receptor changes in response to prolonged treatment with L-dopa.
    Groppetti A, Flauto C, Parati E, Vescovi A, Rusconi L, Parenti M.
    J Neural Transm Suppl; 1986 Mar; 22():33-45. PubMed ID: 2946813
    [Abstract] [Full Text] [Related]

  • 15. A role of the polysynaptic system of substantia nigra in the cholinergic-dopaminergic equilibrium in the central nervous system.
    Wolfarth S, Dulska E, Gołembiowska-Nikitin K, Vetulani J.
    Naunyn Schmiedebergs Arch Pharmacol; 1978 Apr; 302(2):123-31. PubMed ID: 652058
    [No Abstract] [Full Text] [Related]

  • 16. Glial responses associated with dopaminergic striatal reinnervation following lesions of the rat substantia nigra.
    Stanic D, Tripanichkul W, Drago J, Finkelstein DI, Horne MK.
    Brain Res; 2004 Oct 08; 1023(1):83-91. PubMed ID: 15364022
    [Abstract] [Full Text] [Related]

  • 17. Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration.
    Wenning GK, Granata R, Laboyrie PM, Quinn NP, Jenner P, Marsden CD.
    Mov Disord; 1996 Sep 08; 11(5):522-32. PubMed ID: 8866493
    [Abstract] [Full Text] [Related]

  • 18. SCH23390 effects on apomorphine-induced responses of nigral dopaminergic neurons.
    Napier TC, Givens BS, Schulz DW, Bunney BS, Breese GR, Mailman RB.
    J Pharmacol Exp Ther; 1986 Mar 08; 236(3):838-45. PubMed ID: 3512819
    [Abstract] [Full Text] [Related]

  • 19. Enhancement of apomorphine-induced rotational behaviour in rats following the combination of 6-hydroxydopamine and electrolytic lesions in the substantia nigra.
    Watanabe H, Watanabe K.
    Jpn J Pharmacol; 1979 Feb 08; 29(1):93-104. PubMed ID: 459160
    [No Abstract] [Full Text] [Related]

  • 20. Dopaminergic supersensitivity in the striatum.
    Ungerstedt U, Ljungberg T, Hoffer B, Siggins G.
    Adv Neurol; 1975 Feb 08; 9():57-65. PubMed ID: 167568
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.